2021
Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience
Padilla L, Burmeister JW, Burnett OL, Covington EL, Den RB, Dominello MM, Du KL, Galavis PE, Junell S, Kahn J, Kishore M, Mooney K, Mukhopadhyay ND, Studenski MT, Yechieli RL, Fields EC. Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 1058-1065. PMID: 34380009, DOI: 10.1016/j.ijrobp.2021.07.1706.Peer-Reviewed Original ResearchBreaking Tradition to Bridge Bench and Bedside: Accelerating the MD-PhD-Residency Pathway.
Modrek AS, Tanese N, Placantonakis DG, Sulman EP, Rivera R, Du KL, Gerber NK, David G, Chesler M, Philips MR, Cangiarella J. Breaking Tradition to Bridge Bench and Bedside: Accelerating the MD-PhD-Residency Pathway. Academic Medicine 2021, 96: 518-521. PMID: 33464738, DOI: 10.1097/acm.0000000000003920.Peer-Reviewed Original Research
2018
Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis
Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, Daniels IR, Smart NJ, Osborne ME, Beets GL, Maas M, Bitterman DS, Du K, Gollins S, Myint A, Smith FM, Saunders MP, Scott N, O'Dwyer ST, de Castro Araujo RO, Valadao M, Lopes A, Hsiao CW, Lai CL, Smith RK, Paulson EC, Appelt A, Jakobsen A, Wexner SD, Habr-Gama A, Julião G, Perez R, Renehan AG. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. The Lancet Gastroenterology & Hepatology 2018, 3: 825-836. PMID: 30318451, DOI: 10.1016/s2468-1253(18)30301-7.Peer-Reviewed Original ResearchConceptsClinical complete responseIndividual participant dataComplete responseLocal regrowthRectal cancerCumulative incidenceParticipant dataNeoadjuvant chemoradiotherapyHazard ratioSustained clinical complete responseProportion of patientsCenter heterogeneityRecent systematic reviewCox frailty modelStage cT1CT2 tumorsMajor surgeryPrimary outcomeTreatment characteristicsChemoradiotherapyLower riskPatientsStudy heterogeneitySystematic reviewNovel management strategiesDosimetric evaluation of magnetic resonance-generated synthetic CT for radiation treatment of rectal cancer
Wang H, Du K, Qu J, Chandarana H, Das IJ. Dosimetric evaluation of magnetic resonance-generated synthetic CT for radiation treatment of rectal cancer. PLOS ONE 2018, 13: e0190883. PMID: 29304105, PMCID: PMC5755922, DOI: 10.1371/journal.pone.0190883.Peer-Reviewed Original Research
2015
HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era
Grew D, Bitterman D, Leichman CG, Leichman L, Sanfilippo N, Moore HG, Du K. HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era. Diseases Of The Colon & Rectum 2015, 58: 1130-1136. PMID: 26544809, DOI: 10.1097/dcr.0000000000000476.Peer-Reviewed Original ResearchConceptsHIV-negative patientsHIV-positive patientsActive antiretroviral therapy (HAART) eraAntiretroviral therapy eraColostomy-free survivalOverall survival rateAnal cancerSurvival rateTherapy eraMultivariate analysisColostomy-free survival ratesLocal recurrence-free survivalDistant metastasis-free survivalRetrospective chart reviewSmall patient numbersRecurrence-free survivalMetastasis-free survivalOutpatient oncology clinicsLarge academic centerDefinitive chemoradiationDefinitive chemoradiotherapyChart reviewOverall survivalPatient characteristicsHIV infectionMedical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group
Ye JC, Mohindra P, Spektor A, Krishnan MS, Chmura SJ, Howard AR, Viswanathan AN, MacDonald SM, Thaker NG, Das P, Mancini BR, Higgins SA, Braunstein S, Haas-Kogan D, Bradley KA, Hung AY, Thomas CR, Kharofa J, Wheatley M, Currey A, Parashar B, Du K, Jimenez RB, Golden DW. Medical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group. International Journal Of Radiation Oncology • Biology • Physics 2015, 92: 217-219. PMID: 25968822, PMCID: PMC4768460, DOI: 10.1016/j.ijrobp.2015.01.043.Peer-Reviewed Original ResearchRadiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data
Modrek AS, Hsu HC, Leichman CG, Du KL. Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data. Radiation Oncology 2015, 10: 101. PMID: 25902707, PMCID: PMC4464878, DOI: 10.1186/s13014-015-0411-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyDigestive System Surgical ProceduresFemaleHumansKaplan-Meier EstimateMaleMiddle AgedOrganoplatinum CompoundsProportional Hazards ModelsRectal NeoplasmsRetrospective StudiesSEER ProgramSurvival AnalysisUnited StatesConceptsRadiation therapyOverall survivalRectal cancerSurveillance EpidemiologyCell carcinomaSEER dataMultivariate Cox proportional hazards modelCox proportional hazards modelBackgroundSmall cell carcinomaMethodsThe SEER databaseCancer-directed therapyEnd Results (SEER) databaseUnadjusted hazard ratioEnd Results (SEER) dataKaplan-Meier methodOverall survival rateYear of diagnosisSmall cell carcinomaSignificant survival advantagePearson's chi-square testProportional hazards modelOnly significant factorChi-square testChemotherapy usageLocoregional cases
2014
Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials
Min C, Bangalore S, Jhawar S, Guo Y, Nicholson J, Formenti SC, Leichman LP, Du KL. Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials. Oncology 2014, 86: 79-85. PMID: 24435019, DOI: 10.1159/000354641.Peer-Reviewed Original ResearchConceptsDisease-free survivalAdjuvant chemoradiationSurgical resectionOverall survivalRandomized trialsGastric cancerMantel-Haenszel random-effects modelHigher disease-free survivalCategory 1 recommendationNew systemic agentsR0 surgical resectionCurrent national guidelinesSignificant differencesRandom-effects modelAdjuvant chemotherapyPerioperative chemotherapyChemotherapy regimenChemoradiation therapySystemic agentsPrimary outcomeGastric adenocarcinomaClinical trialsChemoradiationNational guidelinesResection
2013
Inhibition of Hsp27 Radiosensitizes Head-and-Neck Cancer by Modulating Deoxyribonucleic Acid Repair
Guttmann DM, Hart L, Du K, Seletsky A, Koumenis C. Inhibition of Hsp27 Radiosensitizes Head-and-Neck Cancer by Modulating Deoxyribonucleic Acid Repair. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: 168-175. PMID: 23849696, DOI: 10.1016/j.ijrobp.2013.05.028.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsCell Line, TumorDNA RepairDNA, NeoplasmDNA-Binding ProteinsGene Knockdown TechniquesHead and Neck NeoplasmsHistonesHSP27 Heat-Shock ProteinsHumansMiceMice, NudeOligonucleotidesProtein Serine-Threonine KinasesRadiation ToleranceRNA, Small InterferingTumor Suppressor ProteinsConceptsShort hairpin RNANeck cancer cell linesCancer cell linesNeck cancerNude miceTumor growthHsp27 knockdownRadiotherapy of headFractionated radiation therapyFaDu human headEffect of Hsp27Cell linesEffective clinical agentRole of HSP27LNA treatmentFlank tumorsRadiation therapyTumor xenograftsDeoxyribonucleic acid repairTumor radiosensitizationClonogenic survivalClinical agentsHairpin RNAHSP27DNA repair signaling
2011
Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials
Du KL, Bae K, Movsas B, Yan Y, Bryan C, Bruner DW. Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials. Supportive Care In Cancer 2011, 20: 1317-1325. PMID: 21720747, DOI: 10.1007/s00520-011-1219-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFollow-Up StudiesHumansKaplan-Meier EstimateLogistic ModelsMaleMarital StatusMiddle AgedPrognosisProportional Hazards ModelsProstatic NeoplasmsRacial GroupsRandomized Controlled Trials as TopicSurvival RateTime FactorsTreatment FailureTreatment OutcomeConceptsPathologic prognostic factorsPrognostic factorsProportional hazards modelOverall survivalMedian timeSociodemographic factorsWhite patientsCancer outcomesPrognostic indicatorProstate cancerMarital statusImproved prostate cancer outcomesHigh-risk cancer patientsGray proportional hazards modelsCommon visceral cancerOutcomes of patientsBiochemical failure rateCumulative incidence methodSignificant prognostic factorsCancer-related outcomesKaplan-Meier methodProstate cancer outcomesGroup of patientsNon-white patientsProstate cancer risk
2010
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma
Du KL, Both S, Friedberg JS, Rengan R, Hahn SM, Cengel KA. Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. Cancer Biology & Therapy 2010, 10: 425-429. PMID: 20699634, DOI: 10.4161/cbt.10.5.12616.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaPlanning treatment volumeExtrapleural pneumonectomyPleural mesotheliomaRadiation therapyImproved local controlMedian radiation doseFuture prospective analysesTreatment of mesotheliomaNew treatment modalitiesIntraoperative photodynamic therapyQuality of lifePhotodynamic therapyIntraoperative adjuvantMultimodality therapyRadiation pneumonitisRespiratory failureSurgical debulkingContralateral lungMPM patientsDoses of radiationMechanical ventilationMultimodality approachLung toxicityTreatment modalities
2007
Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome
Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, Quon H, Lustig R, Weinstein GS, Koch CJ. Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome. International Journal Of Radiation Oncology • Biology • Physics 2007, 69: 1024-1031. PMID: 17967299, PMCID: PMC2737259, DOI: 10.1016/j.ijrobp.2007.04.067.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaPatient outcomesNeck squamous cell tumorsNeck squamous cell carcinomaEvent-free survival timeShorter event-free survival timePositron emission tomographic studiesSquamous cell tumorsLevels of hypoxiaEmission tomographic studiesNodal statusOverall survivalTreatment regimenPrognostic significanceCell tumorsPrimary headMajority of cellsSurvival timeOral cavityHypoxia markersQuantitative immunohistochemistryEF5 bindingSevere hypoxiaPatients
2006
Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer
Du KL, Mick R, Busch TM, Zhu TC, Finlay JC, Yu G, Yodh AG, Malkowicz SB, Smith D, Whittington R, Stripp D, Hahn SM. Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer. Lasers In Surgery And Medicine 2006, 38: 427-434. PMID: 16788929, DOI: 10.1002/lsm.20341.Peer-Reviewed Original ResearchConceptsInterstitial photodynamic therapyProstate adenocarcinomaProstate cancerPhotodynamic therapyRecurrent prostate adenocarcinomaSolid organ diseaseSubsequent tissue necrosisOrgan diseaseDrug levelsPreclinical studiesClinical experienceSTUDY DESIGN/MATERIALSTissue necrosisDose distributionDESIGN/MATERIALSPhase IAdenocarcinomaHuman subjectsProstateCancerTreatmentUniversity of PennsylvaniaDose variationComprehensive treatmentPatients
2004
Megakaryoblastic Leukemia Factor-1 Transduces Cytoskeletal Signals and Induces Smooth Muscle Cell Differentiation from Undifferentiated Embryonic Stem Cells*
Du KL, Chen M, Li J, Lepore JJ, Mericko P, Parmacek MS. Megakaryoblastic Leukemia Factor-1 Transduces Cytoskeletal Signals and Induces Smooth Muscle Cell Differentiation from Undifferentiated Embryonic Stem Cells*. Journal Of Biological Chemistry 2004, 279: 17578-17586. PMID: 14970199, DOI: 10.1074/jbc.m400961200.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlotting, NorthernCell DifferentiationCell NucleusCells, CulturedChromatinCOS CellsCytoplasmCytoskeletonDNA-Binding ProteinsDNA, ComplementaryEmbryo, MammalianGenes, DominantHumansImmunohistochemistryLuciferasesMiceMyocytes, Smooth MuscleNIH 3T3 CellsNuclear ProteinsOncogene Proteins, FusionPlasmidsPrecipitin TestsPromoter Regions, GeneticProtein BindingProtein Structure, TertiaryProtein TransportReverse Transcriptase Polymerase Chain ReactionSignal TransductionStem CellsTissue DistributionTrans-ActivatorsTranscriptional ActivationTransfectionTwo-Hybrid System TechniquesConceptsSmooth muscle cell differentiationMuscle cell differentiationEmbryonic stem cellsPromoter/enhancerSmooth muscle cellsRhoA signalingSM22alpha promoterCell differentiationUndifferentiated embryonic stem cellsSerum response factorTranscription factor myocardinLeucine zipper domainTranscriptional regulatory elementsStem cellsMost human tissuesCytoskeletal signalsTranscriptional programsTransduce signalsMKL1 mutantSMC differentiationZipper domainRegulatory elementsActin polymerizationMKL1 geneSerum stimulation
2003
Myocardin Is a Critical Serum Response Factor Cofactor in the Transcriptional Program Regulating Smooth Muscle Cell Differentiation
Du KL, Ip HS, Li J, Chen M, Dandre F, Yu W, Lu MM, Owens GK, Parmacek MS. Myocardin Is a Critical Serum Response Factor Cofactor in the Transcriptional Program Regulating Smooth Muscle Cell Differentiation. Molecular And Cellular Biology 2003, 23: 2425-2437. PMID: 12640126, PMCID: PMC150745, DOI: 10.1128/mcb.23.7.2425-2437.2003.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsCell DifferentiationCells, CulturedCOS CellsDNA, ComplementaryGene Expression Regulation, DevelopmentalHumansMiceMicrofilament ProteinsMolecular Sequence DataMuscle ProteinsMuscle, SmoothMuscle, Smooth, VascularMyocardiumNuclear ProteinsOrgan SpecificityPromoter Regions, GeneticRatsRNA, Small InterferingSequence AlignmentSerum Response FactorStem CellsTrans-ActivatorsTranscriptional ActivationConceptsSerum response factorExpression of myocardinTranscriptional programsSerum Response Factor CofactorMyocardin geneSRF DNA-binding domainSmooth muscle cell lineageFunction of myocardinSmooth muscle cell differentiationDNA-binding domainMuscle cell lineageMuscle cell differentiationTranscription factor myocardinTranscriptional regulatory elementsUndifferentiated mouse ES cellsEmbryonic stem cellsMouse ES cellsAlpha promoter activitySmooth muscle alpha-actinSM22 alphaMuscle alpha-actinMutant proteinsVisceral SMCsEmbryonic developmentRegulatory elements
2002
SM22β encodes a lineage-restricted cytoskeletal protein with a unique developmentally regulated pattern of expression
Zhang JC, Helmke BP, Shum A, Du K, Yu WW, Lu MM, Davies PF, Parmacek MS. SM22β encodes a lineage-restricted cytoskeletal protein with a unique developmentally regulated pattern of expression. Cells And Development 2002, 115: 161-166. PMID: 12049783, DOI: 10.1016/s0925-4773(02)00088-6.Peer-Reviewed Original ResearchMeSH Keywords3T3 CellsAmino Acid SequenceAnimalsBase SequenceCell LineageCells, CulturedCytoskeletal ProteinsDNA, ComplementaryGene Expression ProfilingGene Expression Regulation, DevelopmentalHumansMiceMolecular Sequence DataMuscle ProteinsMuscle, Smooth, VascularRatsSubcellular FractionsTissue DistributionConceptsCytoskeletal proteinsRegulated patternLineage-restricted patternsMouse embryonic developmentMuscle-specific proteinsCytoskeletal actin filamentsRegulated genesNovel actinNeuron-specific proteinRepeat domainEmbryonic developmentAcid polypeptideSequence identitySpecific proteinsActin filamentsIntracellular signalingLung mesenchymeGastrointestinal epithelial cellsSM22alphaCartilaginous primordiaProteinCellular morphologySmooth muscle cellsEpithelial cellsMuscle cells
2001
Binding of Serum Response Factor to CArG Box Sequences Is Necessary but Not Sufficient to Restrict Gene Expression to Arterial Smooth Muscle Cells*
Strobeck M, Kim S, Zhang J, Clendenin C, Du K, Parmacek M. Binding of Serum Response Factor to CArG Box Sequences Is Necessary but Not Sufficient to Restrict Gene Expression to Arterial Smooth Muscle Cells*. Journal Of Biological Chemistry 2001, 276: 16418-16424. PMID: 11279108, DOI: 10.1074/jbc.m100631200.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated Regions3T3 Cells5' Untranslated RegionsAnimalsAortaArteriesBase SequenceBeta-GalactosidaseBinding SitesCell LineCells, CulturedDNA-Binding ProteinsGene Expression RegulationGenes, fosHeartHeLa CellsHumansMiceMice, TransgenicMicrofilament ProteinsMolecular Sequence DataMuscle ProteinsMuscle, Smooth, VascularNuclear ProteinsPromoter Regions, GeneticRatsSequence DeletionSerum Response FactorTranscription FactorsConceptsSerum response factorBinding of SRFC-fos SRESM22alpha promoterCArG boxBind serum response factorActivity of SRFSmooth muscle cell developmentArterial SMCsMuscle cell developmentResponse factorTransgenic miceProtein binding assaysTransgene expressionBox sequenceDeletion analysisNuclear proteinsSME-1Arterial smooth muscle cellsGene expressionPromoter activityMolecular mechanismsCell developmentPromoterSmooth muscle cells